

RRT and conservative management

NICE guideline: methods

NICE guideline <number>

Methods

April 2018

Draft for Consultation

Developed by the National Guideline Centre

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© National Institute for Health and Care Excellence, 2017

Contents

1	Development of the guideline	5
1.1	What is a NICE guideline?.....	5
1.2	Remit.....	5
1.3	Renal replacement therapy (RRT), including conservative management and transplant.Who developed this guideline?	6
1.3.1	What this guideline covers	6
1.3.2	What this guideline does not cover.....	7
1.3.3	Relationships between the guideline and other NICE guidance	7
2	Methods	9
2.1	Developing the review questions and outcomes.....	9
2.2	Searching for evidence.....	17
2.2.1	Clinical and health economics literature searches.....	17
2.3	Identifying and analysing evidence of effectiveness	17
2.3.1	Inclusion and exclusion criteria	18
2.3.2	Type of studies.....	19
2.3.3	Methods of combining clinical studies	19
2.3.4	Appraising the quality of evidence by outcomes.....	21
2.3.5	Assessing clinical importance	28
2.3.6	Clinical evidence statements.....	28
2.4	Identifying and analysing evidence of cost effectiveness	29
2.4.1	Literature review	29
2.4.2	Undertaking new health economic analysis.....	31
2.4.3	Cost-effectiveness criteria.....	31
2.4.4	In the absence of health economic evidence.....	32
2.5	Developing recommendations	33
2.5.1	Research recommendations	34
2.5.2	Validation process.....	34
2.5.3	Updating the guideline	34
2.5.4	Disclaimer	34
2.5.5	Funding.....	34
3	Additional information	35
4	Acronyms and abbreviations	36
5	Glossary	37
5.1	Guideline-specific terms	37
5.2	General terms	38

1.1 Development of the guideline

1.1.2 What is a NICE guideline?

3 NICE guidelines are recommendations for the care of individuals in specific clinical
4 conditions or circumstances within the NHS – from prevention and self-care through primary
5 and secondary care to more specialised services. These may also include elements of social
6 care or public health measures. We base our guidelines on the best available research
7 evidence, with the aim of improving the quality of healthcare. We use predetermined and
8 systematic methods to identify and evaluate the evidence relating to specific review
9 questions.

10 NICE guidelines can:

- 11 • provide recommendations for the treatment and care of people by health professionals
- 12 • be used to develop standards to assess the clinical practice of individual health
13 professionals
- 14 • be used in the education and training of health professionals
- 15 • help patients to make informed decisions
- 16 • improve communication between patient and health professional.

17 While guidelines assist the practice of healthcare professionals, they do not replace their
18 knowledge and skills.

19 We produce our guidelines using the following steps:

- 20 • A guideline topic is referred to NICE from NHS England.
- 21 • Stakeholders register an interest in the guideline and are consulted throughout the
22 development process.
- 23 • The scope is prepared by the National Guideline Centre (NGC).
- 24 • The NGC establishes a guideline committee.
- 25 • A draft guideline is produced after the group assesses the available evidence and makes
26 recommendations.
- 27 • There is a consultation on the draft guideline.
- 28 • The final guideline is produced.

29 The guideline is made up of a collection of documents including this Methods report and a
30 number of evidence reports covering each of the review questions included in the guideline.
31 These can all be downloaded from NICE at www.nice.org.uk.

32 NICE also publishes a summary of the recommendation in this guideline, known as ‘the
33 NICE guideline’.

34 NICE Pathways brings together all connected NICE guidance.

1.2.5 Remit

36 NICE received the remit for this guideline from NHS England. NICE commissioned the NGC
37 to produce the guideline.

38 The remit for this guideline is:

1.3.1 Renal replacement therapy (RRT), including conservative management and transplant. Who developed this guideline?

3 A multidisciplinary guideline committee comprising health professionals and researchers as
4 well as lay members developed this guideline (see the list of guideline committee members
5 and the acknowledgements).

6 The National Institute for Health and Care Excellence (NICE) funds the National Guideline
7 Centre (NGC) and thus supported the development of this guideline. The committee was
8 convened by the NGC and chaired by Dr Jan Dudley in accordance with guidance from NICE.

9 The group met approximately every 6 weeks during the development of the guideline. At the
10 start of the guideline development process all committee members declared interests
11 including consultancies, fee-paid work, shareholdings, fellowships and support from the
12 healthcare industry. At all subsequent committee meetings, members declared arising
13 conflicts of interest.

14 Members were either required to withdraw completely or for part of the discussion if their
15 declared interest made it appropriate. The details of declared interests and the actions taken
16 are shown in the declaration of interest register for this guideline published on the NICE
17 website.

18 Staff from the NGC provided methodological support and guidance for the development
19 process. The team working on the guideline included a project manager, systematic
20 reviewers (research fellows), health economists and information specialists. They undertook
21 systematic searches of the literature, appraised the evidence, conducted meta-analysis and
22 cost-effectiveness analysis where appropriate and drafted the guideline in collaboration with
23 the committee.

1.3.24 What this guideline covers

25 The population of this guideline is adults (18 and over) with chronic kidney disease (CKD)
26 stages 4 and 5 and children (under 18) with CKD stages 4 and 5. The following clinical areas
27 are covered:

28 1 Assessment

29 2 Information, education and support

30 3 Decision-making

31 4 RRT and conservative management: which option for which person, when and how
32 frequently.

33 5 Recognition of symptoms.

34 6 Fluid restriction and dietary management

35 7 Transferring between forms of RRT

36 8 Discontinuing RRT.

37 9 Coordination of care for people undergoing RRT or conservative care

38 For further details please refer to the scope for this guideline (published on the NICE
39 website) and the review questions in section 2.1.

1.3.21 What this guideline does not cover

- 2 People with CKD stages 1–3 (except in the context of preparing for RRT) are excluded from
3 the guideline. The following areas are not covered:
- 4 1 Management of CKD.
 - 5 2 Management of acute kidney injury.
 - 6 3 Anaemia in CKD.
 - 7 4 Bone mineral disorder and hyperphosphataemia.
 - 8 5 Symptom management (except recognition of symptoms).
 - 9 6 Technical aspects of delivery of RRT – for example, dialysis prescription (except for
10 frequency of sessions), creation and management of dialysis access, transplant surgery,
11 transplant immunosuppression.
 - 12 7 Management of growth in children with CKD.

1.3.33 Relationships between the guideline and other NICE guidance

14 **NICE technology appraisals to be updated by this guidance:** Guidance on home
15 compared with hospital haemodialysis for patients with end-stage renal failure. NICE
16 technology appraisal guidance TA48 (2002)

17

- 18 • Chronic kidney disease (stage 5): peritoneal dialysis (2011) NICE guideline CG125

19

20 **Related NICE technology appraisals:**

21

- 22 • Immunosuppressive therapy for kidney transplant in children and young people. NICE
23 technology appraisal guidance 484 (2017)
- 24 • Immunosuppressive therapy for kidney transplant in adult. NICE technology appraisal
25 guidance 481 (2017)
- 26 • Machine perfusion systems and cold static storage of kidneys from deceased donors.
27 NICE technology appraisal guidance 165 (2009)
- 28 • Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage
29 renal disease on maintenance dialysis therapy. NICE technology appraisal guidance 117
30 (2007)
- 31 • Immunosuppressive therapy for renal transplantation in adults. NICE technology
32 appraisal guidance 85 (2004)
- 33 • Guidance on the use of ultrasound locating devices for placing central venous catheters.
34 NICE technology appraisal guidance 49 (2002)

35

36 **Related NICE guidelines:**

- 37 • Faltering growth: recognition and management of faltering growth in children. NICE
38 guideline NG75 (2017)
- 39 • Multiple frequency bioimpedance devices to guide fluid management in people with
40 chronic kidney disease having dialysis. NICE guideline DG29 (2017)
- 41 • Multimorbidity: clinical assessment and management (2016) NICE clinical guideline NG56

42

- 1 • End of life care for infants, children and young people with life limiting conditions: Planning
- 2 and management. NICE guideline NG61 (2016)
- 3 • Chronic kidney disease: managing anaemia (2015) NICE guideline NG8
- 4 • Chronic kidney disease in adults: assessment and management (2014) NICE guideline
- 5 CG182
- 6 • Acute kidney injury (2013) NICE guideline CG169
- 7 • Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (2013) NICE
- 8 guideline CG157
- 9 • Patient experience in adult NHS services: improving the experience of care for people
- 10 using adult NHS services (2012) NICE clinical guideline
- 11 **Related NICE guidance currently in development:**
- 12 • End of life care for adults in the last year of life: service delivery NICE clinical guideline.
- 13 Publication tba
- 14 • Kidney transplantation (rejection) NICE clinical guideline. Publication tba

2.1 Methods

2 This report sets out in detail the methods used to review the evidence and to develop the
3 recommendations that are presented in each of the evidence reviews for this guideline. This
4 guidance was developed in accordance with the methods outlined in the NICE guidelines
5 manual, 2014 version.²

6 Sections 2.1 and 2.3 describe the process used review clinical evidence (summarised in
7 Figure 1), section 2.2 describes the process used to identify clinical and economic evidence,
8 section 2.4 describes the process used to review the health economic evidence, and section
9 2.5 describes the process used to develop recommendations.

Figure 1: Step-by-step process of review of evidence in the guideline



2.1.10 Developing the review questions and outcomes

11 Review questions were developed using a PICO framework (population, intervention,
12 comparison and outcome) for intervention reviews and using a framework of population,
13 setting and context for qualitative reviews.

14 This use of a framework guided the literature searching process, critical appraisal and
15 synthesis of evidence, and facilitated the development of recommendations by the guideline
16 committee. The review questions were drafted by the NGC technical team and refined and
17 validated by the committee. The questions were based on the key clinical areas identified in
18 the scope.

19 A total of 13 review questions were identified.

- 1 Full literature searches, critical appraisals and evidence reviews were completed for all the
- 2 specified review questions.

3 Table 1: Review questions

Evidence report	Type of review	Review questions	Outcomes
A	Intervention	When should RRT be initiated?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Quality of life • Symptom scores/functional measures • Mortality • Hospitalisation • Other healthcare resource use • Time to failure of RRT form <p>Important outcomes:</p> <ul style="list-style-type: none"> • Psychological distress and mental wellbeing • Cognitive impairment • Patient/family/carer experience of care • Growth (in children) • Malignancy • Adverse Events <ul style="list-style-type: none"> ○ Infections ○ vascular access issues ○ dialysis access issues ○ acute transplant rejection episodes
B	Intervention	<p>What is the clinical and cost effectiveness of different modalities of renal replacement therapies and conservative management for established renal failure?</p> <p>Are there factors which suggest that certain forms of renal replacement therapy may be more appropriate for certain groups of people?</p> <p>Are there groups of people in which conservative management is more appropriate than RRT?</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Quality of life • Symptom scores/functional measures • Mortality • Hospitalisation • Time to failure of RRT form <p>Important outcomes:</p> <ul style="list-style-type: none"> • Psychological distress and mental wellbeing • Preferred place of death • Cognitive impairment • Patient/family/carer experience of care • Growth (in children) • Malignancy • Adverse Events <ul style="list-style-type: none"> ○ Infections ○ vascular access issues ○ dialysis access issues ○ acute transplant rejection episodes

Evidence report	Type of review	Review questions	Outcomes
C	Intervention	What is the clinical and cost effectiveness of different sequences of modalities of renal replacement therapies and conservative management for established renal failure?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related quality of life (continuous) • Mortality (dichotomous and time to event) • Time to failure of RRT form (time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Hospitalisation (rates or continuous) • Preferred place of death (dichotomous) • Symptom scores and functional measures (continuous) • Psychological distress and mental wellbeing (continuous) • Cognitive impairment (dichotomous) • Patient, family and carer experience of care (continuous) • Growth (continuous) • Malignancy (dichotomous) • Adverse events <ul style="list-style-type: none"> ○ Infections (dichotomous) ○ Vascular access issues (dichotomous) ○ Dialysis access issues (dichotomous) ○ Acute transplant rejection episodes (dichotomous)
D	Intervention	What is the most clinical and cost effective way of planning dialysis access formation, transplant listing?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related QoL (continuous) • Mortality (dichotomous and time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Pre-emptive transplantation rates (rates or dichotomous) • Proportion starting on modality of choice (rates or dichotomous) • Proportion with access created/transplant listed who do not go on to require or use RRT (rates or dichotomous)

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> • Psychological distress and mental wellbeing (continuous) • Symptom scores and functional measures (continuous) • Hospitalisation (rates or continuous) • Time to failure of RRT form (time to event) • Patient, family/carer experience of care (continuous) • Adverse events <ul style="list-style-type: none"> ○ Infections (dichotomous) ○ Vascular access issues (dichotomous) ○ Dialysis access issues (dichotomous) ○ Acute transplant rejection episodes (dichotomous)
E	Intervention	When should people with progression to later stages of CKD be assessed for RRT?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related QoL (continuous) • Mortality (dichotomous and time to event) • Hospitalisation (rates or continuous) • Time to failure of RRT form (time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Late referral rates (rates or dichotomous) • Pre-emptive transplantation rates (rates or dichotomous) • Proportion starting on modality of choice (rates or dichotomous) • Proportion receiving RRT after assessment (rates or dichotomous) • Symptom scores and functional measures (continuous) • Psychological distress and mental wellbeing (continuous) • Cognitive impairment (dichotomous)

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> • Patient, family/carer experience of care (continuous) • Growth (continuous) • Malignancy (dichotomous) • Adverse events <ul style="list-style-type: none"> ○ Infections (dichotomous) ○ Vascular access issues (dichotomous) ○ Dialysis access issues (dichotomous) ○ Acute transplant rejection episodes (dichotomous)
F	Intervention	What assessment is needed for people with deteriorating CKD for whom RRT or conservative management may be appropriate?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related QoL (continuous) • Symptom scores and functional measures (continuous) • Mortality (dichotomous and time to event) • Hospitalisation (rates or continuous) • Time to failure of RRT form (time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Psychological distress and mental wellbeing (continuous) • Cognitive impairment (dichotomous) • Patient, family/carer experience of care (continuous) • Growth (continuous) • Malignancy (dichotomous) • Adverse events <ul style="list-style-type: none"> ○ Infections (dichotomous) ○ Vascular access issues (dichotomous) ○ Dialysis access issues (dichotomous) ○ Acute transplant rejection episodes (dichotomous)
G	Intervention	<p>What are the indicators for transferring between the different modalities of RRT?</p> <p>What are the indicators for discontinuing RRT?</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related quality of life (continuous)

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> • Mortality (dichotomous and time to event) • Time to failure of RRT form (time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Hospitalisation (rates or continuous) • Preferred place of death (dichotomous) • Symptom scores and functional measures (continuous) • Psychological distress and mental wellbeing (continuous) • Patient, family and carer experience of care (continuous) • Growth (continuous) • Malignancy (dichotomous) • Adverse events <ul style="list-style-type: none"> ○ Infections (dichotomous) ○ New onset DM/worsening control (dichotomous) ○ Vascular access issues (dichotomous) ○ Dialysis access issues (dichotomous) ○ Acute transplant rejection episodes (dichotomous)
H	Qualitative	What are the most important symptoms to recognise for people undergoing RRT or receiving conservative management?	Symptoms reported by people undergoing RRT or conservative management
I	Intervention	What is the clinical and cost effectiveness of dietary management and fluid restriction for RRT?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related quality of life (continuous) • Mortality (dichotomous and time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Hospitalisation (rates or continuous) • Subjective global assessment or malnutrition universal screen tool (continuous)

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> • Interdialytic weight gain (continuous) • Symptom scores and functional measures (including grip strength, continuous) • Psychological distress and mental wellbeing (continuous) • Blood pressure (continuous) • Patient, family and carer experience of care (continuous) • Growth (continuous) • Adverse events <ul style="list-style-type: none"> ○ Infections (dichotomous) ○ Acute transplant rejection episodes (dichotomous)
J	Intervention	How frequently should people on the different forms of RRT be reviewed?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related quality of life (continuous) • Mortality (dichotomous and time to event) • Time to failure of RRT form (time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Transplantation/transplant listing (rates/dichotomous) • Hospitalisation (rates or continuous) • Preferred place of death (dichotomous) • Symptom scores and functional measures (continuous) • Psychological distress and mental wellbeing (continuous) • Patient, family and carer experience of care (continuous) • Growth (continuous) • Malignancy (dichotomous) • Adverse events <ul style="list-style-type: none"> ○ Infections (dichotomous) ○ Vascular access issues (dichotomous) ○ Dialysis access issues (dichotomous) ○ Acute transplant rejection episodes (dichotomous)

Evidence report	Type of review	Review questions	Outcomes
K	Qualitative	What information, education and support is important for people for whom RRT or conservative management may be appropriate, and their families/carers?	Areas of information, education and support reported by people as important for those approaching (or requiring) RRT or conservative management
L	Intervention	What is the clinical and cost effectiveness of decision support interventions for people who may require renal replacement therapy?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related QoL • Mortality • Decision quality/conflict • Knowledge of relevant decision area • Psychological distress and mental wellbeing • Patient, family/carer experience of care
M	Intervention	What are the most clinical and cost effective ways of co-ordinating care during RRT or conservative management?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Patient, family/carer health-related QoL (continuous) • Symptom scores and functional measures (continuous) • Mortality (dichotomous and time to event) • Hospitalisation or other resource use (rates or continuous) • Time to failure of RRT form (time to event) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Pre-emptive transplantation (dichotomous) • Psychological distress and mental wellbeing (continuous) • Patient, family/carer experience of care (continuous) • Control of co-existing conditions (e.g. HbA1c for DM, BP for hypertension, continuous or dichotomous) <p>Adverse events</p>

2.2.1 Searching for evidence

2.2.1.2 Clinical and health economics literature searches

3 The full search strategy including population terms, intervention terms, study types applied,
4 the databases searched and the years covered can be found in Appendix B of each of the
5 evidence review reports.

6 Systematic literature searches were undertaken to identify all published clinical and health
7 economics evidence relevant to the review questions. Searches were undertaken according
8 to the parameters stipulated within the NICE guidelines manual 2014
9 ([https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf)
10 [guidelines-the-manual.pdf](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf)). Databases were searched using relevant medical subject
11 headings, free-text terms and study-type filters where appropriate. Studies published in
12 languages other than English were not reviewed, where possible, searches were restricted to
13 English Language. All searches were updated on 11 December 2017. If new evidence falls
14 outside of the timeframe for the guideline searches e.g. from stakeholder comments, the
15 impact on the guideline will be considered, and any further action agreed between the
16 developer and NICE staff with a quality assurance role.

17 Prior to running, searches were quality assured using different approaches. Medline search
18 strategies were checked by a second information specialist before being run. Searches were
19 cross-checked with reference lists of highly relevant papers, searches in other systematic
20 reviews analysed, and committee members requested to highlight additional studies.

21 During the scoping stage, a search was conducted for guidelines and reports on the websites
22 listed below. Web sites searched include:

- 23 • Guidelines International Network database (www.g-i-n.net)
- 24 • National Guideline Clearing House (www.guideline.gov)
- 25 • National Institute for Health and Care Excellence (NICE) (www.nice.org.uk)
- 26 • National Institutes of Health Consensus Development Program (consensus.nih.gov)
- 27 • NHS Evidence Search (www.evidence.nhs.uk).

28 Searching for unpublished literature was not undertaken. The NGC and NICE do not have
29 access to drug manufacturers' unpublished clinical trial results, so the clinical evidence
30 considered by the committee for pharmaceutical interventions may be different from that
31 considered by the MHRA and European Medicines Agency for the purposes of licensing and
32 safety regulation.

2.3.3 Identifying and analysing evidence of effectiveness

34 Research fellows conducted the tasks listed below, which are described in further detail in
35 the rest of this section:

- 36 • Identified potentially relevant studies for each review question from the relevant search
37 results by reviewing titles and abstracts. Full papers were then obtained.
- 38 • Reviewed full papers against prespecified inclusion and exclusion criteria to identify
39 studies that addressed the review question in the appropriate population, and reported on
40 outcomes of interest (review protocols are included in an appendix to each of the
41 evidence reports).
- 42 • Critically appraised relevant studies using the appropriate study design checklist as
43 specified in the NICE guidelines manual.² Qualitative studies were critically appraised
44 using the GRADE CERQual approach for rating confidence in the body of evidence as a
45 whole and using an NGC checklist for the methodological limitations section of the quality
46 assessment.

- 1 • Extracted key information about interventional study methods and results using 'Evibase',
2 NGC's purpose-built software. Evibase produces summary evidence tables, including
3 critical appraisal ratings. Key information about non-interventional study methods and
4 results was manually extracted onto standard evidence tables and critically appraised
5 separately (evidence tables are included in an appendix to each of the evidence reports).
- 6 • Generated summaries of the evidence by outcome. Outcome data were combined,
7 analysed and reported according to study design:
 - 8 ○ Randomised data were meta-analysed where appropriate and reported in GRADE
9 profile tables.
 - 10 ○ Data from non-randomised studies were presented as a range of values in GRADE
11 profile tables or meta-analysed if appropriate.
 - 12 ○ Qualitative data were synthesised across studies and presented as summary
13 statements with accompanying GRADE CERQual ratings for each review finding.
- 14 • A sample of a minimum of 10% of the abstract lists of the first 3 sifts by new reviewers
15 and those for complex review questions (for example, prognostic reviews) were double-
16 sifted by a senior research fellow and any discrepancies were rectified. All of the evidence
17 reviews were quality assured by a senior research fellow. This included checking:
 - 18 ○ papers were included or excluded appropriately
 - 19 ○ a sample of the data extractions
 - 20 ○ correct methods were used to synthesise data
 - 21 ○ a sample of the risk of bias assessments.

2.3.22 Inclusion and exclusion criteria

23 The inclusion and exclusion of studies was based on the criteria defined in the review
24 protocols, which can be found in an appendix to each of the evidence reports. Excluded
25 studies (with the reasons for their exclusion) are listed in another appendix to each of the
26 evidence reports. The committee was consulted about any uncertainty regarding inclusion or
27 exclusion.

28 Conference abstracts were not automatically excluded from any review. The abstracts were
29 initially assessed against the inclusion criteria for the review question and further processed
30 when a full publication was not available for that review question. If the abstracts were
31 included the authors were contacted for further information. No relevant conference abstracts
32 were identified for this guideline. Literature reviews, posters, letters, editorials, comment
33 articles, unpublished studies and studies not in English were excluded.

2.3.1.34 Saturation of qualitative studies

35 Data extraction in qualitative reviews is a thorough process and may require more time
36 compared to intervention reviews. It is common practice to stop extracting data once
37 saturation has been reached. This is the point when no new information emerges from
38 studies that match the review protocol.. The remaining identified studies are, however, not
39 directly excluded from the review as they nevertheless fit the criteria defined in the review
40 protocol. Any studies for which data were not extracted due to saturation having been
41 reached, but that fit the inclusion criteria of the protocol, were listed in the table for studies
42 'identified but not included due to saturation' in an appendix to the qualitative evidence
43 review. As an example, tiredness was reported extremely commonly in the qualitative studies
44 on symptom recognition to the point that there were no concerns over data richness. If at that
45 point, a study was found which reported no symptoms other than fatigue, it was not extracted
46 as it was not considered to add any information to the review.

2.3.21 Type of studies

2 Randomised trials, non-randomised intervention studies, and other observational studies
3 (including diagnostic or prognostic studies) were included in the evidence reviews as
4 appropriate.

5 For most intervention reviews in this guideline, parallel randomised controlled trials (RCTs)
6 were included because they are considered the most robust type of study design that can
7 produce an unbiased estimate of the intervention effects. If non-randomised intervention
8 studies were considered appropriate for inclusion (for example, where no randomised
9 evidence was available for critical outcomes) the committee stated a priori in the protocol that
10 either certain identified variables must be equivalent at baseline or else the analysis had to
11 adjust for any baseline differences. If the study did not fulfil either criterion it was excluded.
12 Please refer to the review protocols in each evidence report for full details on the study
13 design of studies selected for each review question.

14 Where data from non-randomised studies were included, the results for each outcome were
15 presented separately for each study or meta-analysed if appropriate.

2.3.36 Methods of combining clinical studies

2.3.3.17 Data synthesis for intervention reviews

18 Where possible, meta-analyses were conducted using Cochrane Review Manager
19 (RevMan5)⁶ software to combine the data given in all studies for each of the outcomes of
20 interest for the review question.

21 All analyses were stratified for age as per the protocols, which meant that different studies
22 with predominant age-groups in different age strata were not combined and analysed
23 together. For some questions additional stratification was used (for example based on BMI),
24 and this is documented in the individual review question protocols in each evidence report.
25 When additional strata were used this led to substrata (for example, using 2 stratification
26 criteria leads to 4 substrata, using 3 stratification criteria leads to 9 substrata) which were
27 analysed separately.

2.3.3.1.28 Analysis of different types of data

29 Dichotomous outcomes

30 Fixed-effects (Mantel–Haenszel) techniques (using an inverse variance method for pooling)
31 were used to calculate risk ratios (relative risk, RR) for the binary outcomes, which included:

- 32 • mortality
- 33 • preferred place of death
- 34 • cognitive impairment
- 35 • malignancy
- 36 • adverse events.

37 Rate ratios were used for hospitalisations as the committee agreed that people requiring
38 RRT were likely to incur multiple hospitalisations in a single year and therefore potentially
39 across trial follow-up periods.

40 The absolute risk difference was also calculated using GRADEpro¹ software, using the
41 median event rate in the control arm of the pooled results.

42 For binary variables where there were zero events in either arm or a less than 1% event rate,
43 Peto odds ratios, rather than risk ratios, were calculated. Peto odds ratios are more
44 appropriate for data with a low number of events.

1 Where sufficient information was provided, hazard ratios were calculated in preference for
2 outcomes such as mortality where the time to the event occurring was important for decision-
3 making.

4 **Continuous outcomes**

5 Continuous outcomes were analysed using an inverse variance method for pooling weighted
6 mean differences. These outcomes included:

- 7 • health-related quality of life (HRQoL)
- 8 • length of stay in hospital
- 9 • symptom scores and functional measures
- 10 • patient, family or carer experience of care
- 11 • psychological distress and mental wellbeing
- 12 • function and activities of daily living.

13 Where the studies within a single meta-analysis had different scales of measurement,
14 standardised mean differences were used (providing all studies reported either change from
15 baseline or final values rather than a mixture of both); each different measure in each study
16 was 'normalised' to the standard deviation value pooled between the intervention and
17 comparator groups in that same study.

18 The means and standard deviations of continuous outcomes are required for meta-analysis.
19 However, in cases where standard deviations were not reported, the standard error was
20 calculated if the p values or 95% confidence intervals (95% CI) were reported, and meta-
21 analysis was undertaken with the mean and standard error using the generic inverse
22 variance method in Cochrane Review Manager (RevMan5⁶) software. Where p values were
23 reported as 'less than', a conservative approach was undertaken. For example, if a p value
24 was reported as 'p≤0.001', the calculations for standard deviations were based on a p value
25 of 0.001. If these statistical measures were not available then the methods described in
26 section 16.1.3 of the Cochrane Handbook (version 5.1.0, updated March 2011) were applied.

2.3.3.1.27 **Generic inverse variance**

28 If a study reported only the summary statistic and 95% CI the generic-inverse variance
29 method was used to enter data into RevMan5.⁶ If the control event rate was reported this
30 was used to generate the absolute risk difference in GRADEpro.¹ If multivariate analysis was
31 used to derive the summary statistic but no adjusted control event rate was reported no
32 absolute risk difference was calculated.

2.3.3.1.33 **Heterogeneity**

34 Statistical heterogeneity was assessed for each meta-analysis estimate by considering the
35 chi-squared test for significance at p<0.1 or an I-squared (I²) inconsistency statistic (with an I-
36 squared value of more than 50% indicating significant heterogeneity) as well as the
37 distribution of effects. Where significant heterogeneity was present, studies were subgrouped
38 based on predefined categories specified by the committee at the protocol setting stage.

39 If the subgroup analysis resolved heterogeneity within all of the derived subgroups, then
40 each of the derived subgroups were adopted as separate analyses of outcomes (providing at
41 least 1 study remained in each subgroup. Assessments of potential differences in effect
42 between subgroups were based on the chi-squared tests for heterogeneity statistics between
43 subgroups. Any subgroup differences were interpreted with caution as separating the groups
44 breaks the study randomisation and as such is subject to uncontrolled confounding.

1 For some questions additional subgrouping was applied, and this is documented in the
2 individual review question protocols. These additional subgrouping strategies were applied
3 independently, so subunits of subgroups were not created, unlike the situation with strata.

4 If all predefined strategies of subgrouping were unable to explain statistical heterogeneity
5 within each derived subgroup, then a random effects (DerSimonian and Laird) model was
6 employed to the entire group of studies in the meta-analysis. A random-effects model
7 assumes a distribution of populations, rather than a single population. This leads to a
8 widening of the confidence interval around the overall estimate, thus providing a more
9 realistic interpretation of the true distribution of effects across more than 1 population. If,
10 however, the committee considered the heterogeneity was so large that meta-analysis was
11 inappropriate, then the results were described narratively.

2.3.3.1.42 Complex analysis

13 Where studies had used a crossover design, paired continuous data were extracted where
14 possible, and forest plots were generated in RevMan5⁶ with the generic inverse variance
15 function. When a crossover study had categorical data and the number of subjects with an
16 event in both interventions was known, the standard error (of the log of the risk ratio) was
17 calculated using the simplified Mantel–Haenszel method for paired outcomes. Forest plots
18 were also generated in RevMan5⁶ with the generic inverse variance function. If paired
19 continuous or categorical data were not available from the crossover studies, the separate
20 group data were analysed in the same way as data from parallel groups, on the basis that
21 this approach would overestimate the confidence intervals and thus artificially reduce study
22 weighting resulting in a conservative effect. Where a meta-analysis included a mixture of
23 studies using both paired and parallel group approaches, all data were entered into
24 RevMan5⁶ using the generic inverse variance function.

2.3.3.25 Data synthesis for qualitative study reviews

26 The main findings for each included paper were identified and thematic analysis methods
27 were used to synthesise this information into broad overarching themes which were
28 summarised into the main review findings. The evidence was presented in the form of a
29 narrative summary detailing the evidence from the relevant papers and how this informed the
30 overall review finding plus a statement on the level of confidence for that review finding.
31 Considerable limitations and issues around relevance were listed. A summary evidence table
32 with the succinct summary statements for each review finding was produced including the
33 associated quality assessment.

2.3.44 Appraising the quality of evidence by outcomes

2.3.4.35 Intervention reviews

36 The evidence for outcomes from the included RCTs and, where appropriate, non-randomised
37 intervention studies, were evaluated and presented using an adaptation of the 'Grading of
38 Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed
39 by the international GRADE working group (<http://www.gradeworkinggroup.org/>). The
40 software (GRADEpro¹) developed by the GRADE working group was used to assess the
41 quality of each outcome, taking into account individual study quality and the meta-analysis
42 results.

43 Each outcome was first examined for each of the quality elements listed and defined in Table
44 2.

1 **Table 2: Description of quality elements in GRADE for intervention studies**

Quality element	Description
Risk of bias	Limitations in the study design and implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis).
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question.
Inconsistency	Inconsistency refers to an unexplained heterogeneity of effect estimates between studies in the same meta-analysis.
Imprecision	Results are imprecise when studies include relatively few patients and few events (or highly variable measures) and thus have wide confidence intervals around the estimate of the effect relative to clinically important thresholds. 95% confidence intervals denote the possible range of locations of the true population effect at a 95% probability, and so wide confidence intervals may denote a result that is consistent with conflicting interpretations (for example a result may be consistent with both clinical benefit AND clinical harm) and thus be imprecise.
Publication bias	Publication bias is a systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication of studies. A closely related phenomenon is where some papers fail to report an outcome that is inconclusive, thus leading to an overestimate of the effectiveness of that outcome.
Other issues	Sometimes randomisation may not adequately lead to group equivalence of confounders, and if so this may lead to bias, which should be taken into account. Potential conflicts of interest, often caused by excessive pharmaceutical company involvement in the publication of a study, should also be noted.

2 Details of how the 4 main quality elements (risk of bias, indirectness, inconsistency and
3 imprecision) were appraised for each outcome are given below. Publication or other bias was
4 only taken into consideration in the quality assessment if it was apparent.

2.3.4.1.15 Risk of bias

6 The main domains of bias for RCTs are listed in Table 3. Each outcome had its risk of bias
7 assessed within each study first. For each study, if there were no risks of bias in any domain,
8 the risk of bias was given a rating of 0. If there was risk of bias in just 1 domain, the risk of
9 bias was given a 'serious' rating of -1, but if there was risk of bias in 2 or more domains the
10 risk of bias was given a 'very serious' rating of -2. A weighted average score was then
11 calculated across all studies contributing to the outcome, by taking into account the weighting
12 of studies according to study precision. For example if the most precise studies tended to
13 each have a score of -1 for that outcome, the overall score for that outcome would tend
14 towards -1.

15 **Table 3: Principle domains of bias in randomised controlled trials**

Limitation	Explanation
Selection bias (sequence generation and allocation concealment)	If those enrolling patients are aware of the group to which the next enrolled patient will be allocated, either because of a non-random sequence that is predictable, or because a truly random sequence was not concealed from the researcher, this may translate into systematic selection bias. This may occur if the researcher chooses not to recruit a participant into that specific group because of: <ul style="list-style-type: none"> • knowledge of that participant's likely prognostic characteristics, and • a desire for one group to do better than the other.

Limitation	Explanation
Performance and detection bias (lack of blinding of patients and healthcare professionals)	Patients, caregivers, those adjudicating or recording outcomes, and data analysts should not be aware of the arm to which patients are allocated. Knowledge of the group can influence: <ul style="list-style-type: none"> • the experience of the placebo effect • performance in outcome measures • the level of care and attention received, and • the methods of measurement or analysis all of which can contribute to systematic bias.
Attrition bias	Attrition bias results from an unaccounted for loss of data beyond a certain level (a differential of 10% between groups). Loss of data can occur when participants are compulsorily withdrawn from a group by the researchers (for example, when a per-protocol approach is used) or when participants do not attend assessment sessions. If the missing data are likely to be different from the data of those remaining in the groups, and there is a differential rate of such missing data from groups, systematic attrition bias may result.
Selective outcome reporting	Reporting of some outcomes and not others on the basis of the results can also lead to bias, as this may distort the overall impression of efficacy.
Other limitations	For example: <ul style="list-style-type: none"> • Stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules. • Use of unvalidated patient-reported outcome measures. • Lack of washout periods to avoid carry-over effects in crossover trials. • Recruitment bias in cluster-randomised trials.

1 The assessment of risk of bias differs for non-randomised intervention studies, as they are
2 inherently at high risk of selection bias. For this reason, GRADE requires that non-
3 randomised evidence is initially downgraded on the basis of study design, starting with a
4 rating of -2. This accounts for selection bias and so non-randomised intervention studies are
5 not downgraded any further on that domain. Non-randomised evidence was assessed
6 against the remaining domains used for RCTs in Table 3, and downgraded further as
7 appropriate.

2.3.4.1.28 *Indirectness*

9 Indirectness refers to the extent to which the populations, interventions, comparisons and
10 outcome measures are dissimilar to those defined in the inclusion criteria for the reviews.
11 Indirectness is important when these differences are expected to contribute to a difference in
12 effect size, or may affect the balance of harms and benefits considered for an intervention.
13 As for the risk of bias, each outcome had its indirectness assessed within each study first.
14 For each study, if there were no sources of indirectness, indirectness was given a rating of 0.
15 If there was indirectness in just 1 source (for example in terms of population), indirectness
16 was given a 'serious' rating of -1, but if there was indirectness in 2 or more sources (for
17 example, in terms of population and treatment) the indirectness was given a 'very serious'
18 rating of -2. A weighted average score was then calculated across all studies contributing to
19 the outcome by taking into account study precision. For example, if the most precise studies
20 tended to have an indirectness score of -1 each for that outcome, the overall score for that
21 outcome would tend towards -1.

2.3.4.1.32 *Inconsistency*

23 Inconsistency refers to an unexplained heterogeneity of results for an outcome across
24 different studies. When estimates of the treatment effect across studies differ widely, this
25 suggests true differences in the underlying treatment effect, which may be due to differences
26 in populations, settings or doses. When heterogeneity existed within an outcome (chi-
27 squared $p < 0.1$, or $I^2 > 50\%$), but no plausible explanation could be found, the quality of

1 evidence for that outcome was downgraded. Inconsistency for that outcome was given a
2 'serious' score of -1 if the I^2 was 50–74%, and a 'very serious' score of -2 if the I^2 was 75%
3 or more.

4 If inconsistency could be explained based on prespecified subgroup analysis (that is, each
5 subgroup had an $I^2 < 50\%$), the committee took this into account and considered whether to
6 make separate recommendations for the subgroups that resolved the heterogeneity. In such
7 a situation the quality of evidence was not downgraded for those emergent outcomes.

8 Since the inconsistency score was based on the meta-analysis results, the score
9 represented the whole outcome and so weighted averaging across studies was not
10 necessary.

2.3.4.1.41 *Imprecision*

12 The criteria applied for imprecision were based on the 95% CIs for the pooled estimate of
13 effect, and the minimal important differences (MID) for the outcome. The MIDs are the
14 threshold for appreciable benefits and harms, separated by a zone either side of the line of
15 no effect where there is assumed to be no clinically important effect. If either end of the 95%
16 CI of the overall estimate of effect crossed 1 of the MID lines, imprecision was regarded as
17 serious and a 'serious' score of -1 was given. This was because the overall result, as
18 represented by the span of the confidence interval, was consistent with 2 interpretations as
19 defined by the MID (for example, both no clinically important effect and clinical benefit were
20 possible interpretations). If both MID lines were crossed by either or both ends of the 95% CI
21 then imprecision was regarded as very serious and a 'very serious' score of -2 was given.
22 This was because the overall result was consistent with all 3 interpretations defined by the
23 MID (no clinically important effect, clinical benefit and clinical harm). This is illustrated in
24 Figure 2. As for inconsistency, since the imprecision score was based on the meta-analysis
25 results, the score represented the whole outcome and so weighted averaging across studies
26 was not necessary.

27 The position of the MID lines is ideally determined by values reported in the literature.
28 'Anchor-based' methods aim to establish clinically meaningful changes in a continuous
29 outcome variable by relating or 'anchoring' them to patient-centred measures of clinical
30 effectiveness that could be regarded as gold standards with a high level of face validity. For
31 example, a MID for an outcome could be defined by the minimum amount of change in that
32 outcome necessary to make patients feel their quality of life had 'significantly improved'.
33 MIDs reported in the literature may also be based on expert clinician or consensus opinion
34 concerning the minimum amount of change in a variable deemed to affect quality of life or
35 health. For binary variables, any MIDs reported in the literature will inevitably be based on
36 expert consensus, as such MIDs relate to all-or-nothing population effects rather than
37 measurable effects on an individual, and so are not amenable to patient-centred 'anchor'
38 methods.

39 In the absence of values identified in the literature, the alternative approach to deciding on
40 MID levels is the 'default' method, as follows:

- 41 • For categorical outcomes the MIDs were taken to be RRs of 0.80 and 1.25. For 'positive'
42 outcomes such as 'patient satisfaction', the RR of 0.80 is taken as the line denoting the
43 boundary between no clinically important effect and a clinically significant harm, whilst the
44 RR of 1.25 is taken as the line denoting the boundary between no clinically important
45 effect and a clinically significant benefit. For 'negative' outcomes such as 'bleeding', the
46 opposite occurs, so the RR of 0.80 is taken as the line denoting the boundary between no
47 clinically important effect and a clinically significant benefit, whilst the RR of 1.25 is taken
48 as the line denoting the boundary between no clinically important effect and a clinically
49 significant harm.
- 50 • For continuous outcome variables the MID was taken as half the median baseline
51 standard deviation of that variable, across all studies in the meta-analysis. Hence the MID


1 denoting the minimum clinically significant benefit was positive for a 'positive' outcome (for
2 example, a quality of life measure where a higher score denotes better health), and
3 negative for a 'negative' outcome (for example, a visual analogue scale [VAS] pain score).
4 Clinically significant harms will be the converse of these. If baseline values are
5 unavailable, then half the median comparator group standard deviation of that variable will
6 be taken as the MID.
7 • If standardised mean differences have been used, then the MID will be set at the absolute
8 value of +0.5. This follows because standardised mean differences are mean differences
9 normalised to the pooled standard deviation of the 2 groups, and are thus effectively
10 expressed in units of 'numbers of standard deviations'. The 0.5 MID value in this context
11 therefore indicates half a standard deviation, the same definition of MID as used for non-
12 standardised mean differences.

13 The default MID value was subject to amendment after discussion with the committee. If the
14 committee decided that the MID level should be altered, after consideration of absolute as
15 well as relative effects, this was allowed, provided that any such decision was not influenced
16 by any bias towards making stronger or weaker recommendations for specific outcomes.

17 For this guideline, the default method was adopted except for mortality and modality failure
18 where the committee agreed, based on their consensus, that the 0.8 to 1.25 MIDs were too
19 wide and decided on the use of 0.9 to 1.11 instead.

20

Figure 2: Illustration of precise and imprecise outcomes based on the 95% CI of dichotomous outcomes in a forest plot (Note that all 3 results would be pooled estimates, and would not, in practice, be placed on the same forest plot)



2.3.4.1.51 Overall grading of the quality of clinical evidence

22 Once an outcome had been appraised for the main quality elements, as above, an overall
23 quality grade was calculated for that outcome. The scores (0, -1 or -2) from each of the
24 main quality elements were summed to give a score that could be anything from 0 (the best
25 possible) to -8 (the worst possible). However scores were capped at -3. This final score was
26 then applied to the starting grade that had originally been applied to the outcome by default,

1 based on study design. All RCTs started as High and the overall quality became Moderate,
2 Low or Very Low if the overall score was -1, -2 or -3 points respectively. The significance of
3 these overall ratings is explained in Table 4. The reasons for downgrading in each case were
4 specified in the footnotes of the GRADE tables.

5 Non-randomised intervention studies started at Low, and so a score of -1 would be enough
6 to take the grade to the lowest level of Very Low. Non-randomised intervention studies could,
7 however, be upgraded if there was a large magnitude of effect or a dose-response gradient.

8 **Table 4: Overall quality of outcome evidence in GRADE**

Level	Description
High	Further research is very unlikely to change our confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low	Any estimate of effect is very uncertain

2.3.4.29 Qualitative reviews

10 Review findings from the included qualitative studies were evaluated and presented using
11 the 'Confidence in the Evidence from Reviews of Qualitative Research' (CERQual) Approach
12 developed by the GRADE-CERQual Project Group, a subgroup of the GRADE Working
13 Group.

14 The CERQual Approach assesses the extent to which a review finding is a reasonable
15 representation of the phenomenon of interest (the focus of the review question). Each review
16 finding was assessed for each of the 4 quality elements listed and defined below in Table 5.

17 **Table 5: Description of quality elements in GRADE-CERQual for qualitative studies**

Quality element	Description
Methodological limitations	The extent of problems in the design or conduct of the included studies that could decrease the confidence that the review finding is a reasonable representation of the phenomenon of interest. Assessed at the study level using an NGC checklist.
Coherence	The extent to which the reviewer is able to identify a clear pattern across the studies included in the review.
Relevance	The extent to which the body of evidence from the included studies is applicable to the context (study population, phenomenon of interest, setting) specified in the protocol.
Adequacy	The degree of the confidence that the review finding is being supported by sufficient data. This is an overall determination of the richness (depth of analysis) and quantity of the evidence supporting a review finding or theme.

18 Details of how the 4 quality elements (methodological limitations, coherence, relevance and
19 adequacy) were appraised for each review finding are given below.

2.3.4.2.20 Methodological limitations

21 Each review finding had its methodological limitations assessed within each study first using
22 an NGC checklist. Based on the degree of methodological limitations studies were evaluated
23 as having minor, moderate or severe limitations. The questions to be answered in the
24 checklist below included:

- 25 • Was qualitative design an appropriate approach?

- 1 • Was the study approved by an ethics committee?
 - 2 • Was the study clear in what it sought to do?
 - 3 • Is the context clearly described?
 - 4 • Is the role of the researcher clearly described?
 - 5 • Are the research design and methods rigorous?
 - 6 • Was the data collection rigorous?
 - 7 • Was the data analysis rigorous?
 - 8 • Are the data rich?
 - 9 • Are the findings relevant to the aims of the study?
 - 10 • Are the findings and conclusions convincing?
- 11 The overall assessment of the methodological limitations of the evidence was based on the
12 primary studies contributing to the review finding. The relative contribution of each study to
13 the overall review finding and of the type of methodological limitation(s) were taken into
14 account when giving an overall rating.

2.3.4.2.25 Coherence

16 Coherence is the extent to which the reviewer is able to identify a clear pattern across the
17 studies included in the review, and if there is variation present (contrasting or disconfirming
18 data) whether this variation is explained by the contributing study authors. If a review finding
19 in 1 study does not support the main finding and there is no plausible explanation for this
20 variation, then the confidence that the main finding reasonably reflects the phenomenon of
21 interest is decreased. Each review finding was given a rating of minor, moderate or major
22 concerns about coherence.

2.3.4.2.23 Relevance

24 Relevance is the extent to which the body of evidence from the included studies is applicable
25 to the context (study population, phenomenon of interest, setting) specified in the protocol.
26 As such, relevance is dependent on the individual review and discussed with the guideline
27 committee. Relevance is categorised in 3 ways: partial relevance, indirect relevance and no
28 concerns about relevance.

2.3.4.2.29 Adequacy

30 The judgement of adequacy is based on the confidence of the finding being supported by
31 sufficient data. This is an overall determination of the richness (depth of analysis) and
32 quantity of the evidence supporting a review finding or theme. Rich data provide sufficient
33 detail to gain an understanding of the theme or review finding, whereas thin data do not
34 provide enough detail for an adequate understanding. Quantity of data is the second pillar of
35 the assessment of adequacy. For review findings that are only supported by 1 study or data
36 from only a small number of participants, the confidence that the review finding reasonable
37 represents the phenomenon of interest might be decreased. As with richness of data,
38 quantity of data is review dependent. Based on the overall judgement of adequacy, a rating
39 of no concerns, minor concerns, or substantial concerns about adequacy was given.

2.3.4.2.50 Overall judgement of the level of confidence for a review finding

41 GRADE-CERQual is used to assess the body of evidence as a whole through a confidence
42 rating representing the extent to which a review finding is a reasonable representation of the
43 phenomenon of interest. The 4 components (methodological limitations, coherence,
44 relevance and adequacy) are used in combination to form an overall judgement. GRADE-
45 CERQual uses 4 levels of confidence: high, moderate, low and very low confidence. The
46 significance of these overall ratings is explained in Table 6. Each review finding starts at a
47 high level of confidence and is downgraded based on the concerns identified in any 1 or

1 more of the 4 components. Quality assessment of qualitative reviews is a subjective
2 judgement by the reviewer based on the concerns that have been noted. A detailed
3 explanation of how such a judgement had been made was included in the narrative
4 summary.

5 **Table 6: Overall level of confidence for a review finding in GRADE-CERQual**

Level	Description
High confidence	It is highly likely that the review finding is a reasonable representation of the phenomenon of interest.
Moderate confidence	It is likely that the review finding is a reasonable representation of the phenomenon of interest.
Low confidence	It is possible that the review finding is a reasonable representation of the phenomenon of interest.
Very low confidence	It is not clear whether the review finding is a reasonable representation of the phenomenon of interest.

2.3.56 Assessing clinical importance

7 The committee assessed the evidence by outcome in order to determine if there was, or
8 potentially was, a clinically important benefit, a clinically important harm or no clinically
9 important difference between interventions. To facilitate this, binary outcomes were
10 converted into absolute risk differences (ARDs) using GRADEpro¹ software: the median
11 control group risk across studies was used to calculate the ARD and its 95% CI from the
12 pooled risk ratio.

13 The assessment of clinical benefit, harm, or no benefit or harm was based on the point
14 estimate of absolute effect for intervention studies, which was standardised across the
15 reviews. The committee considered for most of the outcomes in the intervention reviews that
16 if at least 100 more participants per 1000 (10%) achieved the outcome of interest in the
17 intervention group compared to the comparison group for a positive outcome then this
18 intervention was considered beneficial. The same point estimate but in the opposite direction
19 applied for a negative outcome. For the critical outcomes of mortality and modality failure a
20 change of at least 30 participants per 1000 (3%) represented a clinical important effect. For
21 continuous outcomes if the mean difference was greater than the minimally important
22 difference (MID) then this represented a clinical benefit or harm. Where absolute effects
23 could not be calculated, the relative effect MIDs were used as the starting point for the
24 committee's consideration of the importance of each outcome.

2.3.65 Clinical evidence statements

26 Clinical evidence statements are summary statements that are included in each evidence
27 report, and which summarise the key features of the clinical effectiveness evidence
28 presented. The wording of the evidence statements reflects the certainty or uncertainty in the
29 estimate of effect. The evidence statements are presented by outcome and encompass the
30 following key features of the evidence:

- 31 • The number of studies for a particular outcome.
- 32 • An indication of the direction of clinical importance (if one treatment is beneficial or
33 harmful compared to the other, or whether there is no difference between the 2 tested
34 treatments).
- 35 • A description of the overall quality of the evidence (GRADE overall quality).

2.4.1 Identifying and analysing evidence of cost effectiveness

2 The committee is required to make decisions based on the best available evidence of both
3 clinical effectiveness and cost effectiveness. Guideline recommendations should be based
4 on the expected costs of the different options in relation to their expected health benefits
5 (that is, their 'cost effectiveness') rather than the total implementation cost. However, the
6 committee will also need to be increasingly confident in the cost effectiveness of a
7 recommendation as the cost of implementation increases. Therefore, the committee may
8 require more robust evidence on the effectiveness and cost effectiveness of any
9 recommendations that are expected to have a substantial impact on resources; any
10 uncertainties must be offset by a compelling argument in favour of the recommendation. The
11 cost impact or savings potential of a recommendation should not be the sole reason for the
12 committee's decision.²

13 Health economic evidence was sought relating to the key clinical issues being addressed in
14 the guideline. Health economists:

- 15 • Undertook a systematic review of the published economic literature.
- 16 • Undertook new cost-effectiveness analysis in priority areas.

2.4.1.7 Literature review

18 The health economists:

- 19 • Identified potentially relevant studies for each review question from the health economic
20 search results by reviewing titles and abstracts. Full papers were then obtained.
- 21 • Reviewed full papers against prespecified inclusion and exclusion criteria to identify
22 relevant studies (see below for details).
- 23 • Critically appraised relevant studies using economic evaluations checklists as specified in
24 the NICE guidelines manual.²
- 25 • Extracted key information about the studies' methods and results into health economic
26 evidence tables (which can be found in appendices to the relevant evidence reports).
- 27 • Generated summaries of the evidence in NICE health economic evidence profile tables
28 (included in the relevant evidence report for each review question) – see below for details.

2.4.1.29 Inclusion and exclusion criteria

30 Full economic evaluations (studies comparing costs and health consequences of alternative
31 courses of action: cost–utility, cost-effectiveness, cost–benefit and cost–consequences
32 analyses) and comparative costing studies that addressed the review question in the relevant
33 population were considered potentially includable as health economic evidence.

34 Studies that only reported cost per hospital (not per patient), or only reported average cost
35 effectiveness without disaggregated costs and effects were excluded. Literature reviews,
36 abstracts, posters, letters, editorials, comment articles, unpublished studies and studies not
37 in English were excluded. Studies published before 2001 and studies from non-OECD
38 countries or the USA were also excluded, on the basis that the applicability of such studies to
39 the present UK NHS context is likely to be too low for them to be helpful for decision-making.

40 Relevant health economic studies were assessed for applicability to the development of this
41 guideline and methodological quality. Excluded studies are detailed in the exclusion table in
42 each evidence report with the reason. Where multiple studies were includable these were
43 prioritised for inclusion based on their relative applicability and quality. For example, if a high
44 quality, directly applicable UK analysis was available, then other less relevant studies may
45 not have been included. Where exclusions occurred on this basis, this is noted in the
46 relevant evidence report.

1 For more details about the assessment of applicability and methodological quality see Table
2 7 below and the economic evaluation checklist (appendix H of the NICE guidelines manual²)
3 and the health economics review protocol, which can be found in each of the evidence
4 reports.

5 When no relevant health economic studies were found from the economic literature review,
6 relevant UK NHS unit costs related to the compared interventions were presented to the
7 committee to inform the possible economic implications of the recommendations.

2.4.1.28 NICE health economic evidence profiles

9 NICE health economic evidence profile tables were used to summarise cost and cost-
10 effectiveness estimates for the included health economic studies in each evidence review
11 report. The health economic evidence profile shows an assessment of applicability and
12 methodological quality for each economic study, with footnotes indicating the reasons for the
13 assessment. These assessments were made by the health economist using the economic
14 evaluation checklist from the NICE guidelines manual.² It also shows the incremental costs,
15 incremental effects (for example, quality-adjusted life years [QALYs]) and incremental cost-
16 effectiveness ratio (ICER) for the base case analysis in the study, as well as information
17 about the assessment of uncertainty in the analysis. See Table 7 for more details.

18 When a non-UK study was included in the profile, the results were converted into pounds
19 sterling using the appropriate purchasing power parity.⁵

20 **Table 7: Content of NICE health economic evidence profile**

Item	Description
Study	Surname of first author, date of study publication and country perspective with a reference to full information on the study.
Applicability	An assessment of applicability of the study to this guideline, the current NHS situation and NICE decision-making: ^(a) <ul style="list-style-type: none"> • Directly applicable – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness. • Partially applicable – the study fails to meet 1 or more applicability criteria, and this could change the conclusions about cost effectiveness. • Not applicable – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.
Limitations	An assessment of methodological quality of the study: ^(a) <ul style="list-style-type: none"> • Minor limitations – the study meets all quality criteria, or fails to meet 1 or more quality criteria, but this is unlikely to change the conclusions about cost effectiveness. • Potentially serious limitations – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost effectiveness. • Very serious limitations – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.
Other comments	Information about the design of the study and particular issues that should be considered when interpreting it.
Incremental cost	The mean cost associated with one strategy minus the mean cost of a comparator strategy.
Incremental effects	The mean QALYs (or other selected measure of health outcome) associated with one strategy minus the mean QALYs of a comparator strategy.
Cost effectiveness	Incremental cost-effectiveness ratio (ICER): the incremental cost divided by the incremental effects (usually in £ per QALY gained).

Item	Description
Uncertainty	A summary of the extent of uncertainty about the ICER reflecting the results of deterministic or probabilistic sensitivity analyses, or stochastic analyses of trial data, as appropriate.

1 (a) *Applicability and limitations were assessed using the economic evaluation checklist in appendix H of the NICE*
2 *guidelines manual*²

2.4.23 Undertaking new health economic analysis

4 As well as reviewing the published health economic literature for each review question, as
5 described above, new health economic analysis was undertaken by the health economist in
6 selected areas. Priority areas for new analysis were agreed by the committee after formation
7 of the review questions and consideration of the existing health economic evidence.

8 The committee identified HDF versus HD as the highest priority area for original health
9 economic modelling. The clinical evidence supported the use of HDF but there was potential
10 for additional costs and uncertainty in the published cost effectiveness evidence. In addition,
11 a recommendation for HDF was considered to be a change in practice that may have a
12 substantial resource impact to the NHS in England. For more detail see Evidence report B:
13 Modalities of RRT.

14 The following general principles were adhered to in developing the cost-effectiveness
15 analysis:

- 16 • Methods were consistent with the NICE reference case for interventions with health
17 outcomes in NHS settings.^{2, 4}
- 18 • The committee was involved in the design of the model, selection of inputs and
19 interpretation of the results.
- 20 • Model inputs were based on the systematic review of the clinical literature supplemented
21 with other published data sources where possible.
- 22 • When published data were not available committee expert opinion was used to populate
23 the model.
- 24 • Model inputs and assumptions were reported fully and transparently.
- 25 • The results were subject to sensitivity analysis and limitations were discussed.
- 26 • The model was peer-reviewed by another health economist at the NGC.

27 Full methods and results of the cost-effectiveness analysis for HDF versus HD are described
28 in a separate economic analysis report.

2.4.29 Cost-effectiveness criteria

30 NICE's report 'Social value judgements: principles for the development of NICE guidance'
31 sets out the principles that committees should consider when judging whether an intervention
32 offers good value for money.³ In general, an intervention was considered to be cost effective
33 (given that the estimate was considered plausible) if either of the following criteria applied:

- 34 • the intervention dominated other relevant strategies (that is, it was both less costly in
35 terms of resource use and more clinically effective compared with all the other relevant
36 alternative strategies), or
- 37 • the intervention cost less than £20,000 per QALY gained compared with the next best
38 strategy.

39 If the committee recommended an intervention that was estimated to cost more than £20,000
40 per QALY gained, or did not recommend one that was estimated to cost less than £20,000
41 per QALY gained, the reasons for this decision are discussed explicitly in 'The committee's
42 discussion of the evidence' section of the relevant evidence report, with reference to issues

1 regarding the plausibility of the estimate or to the factors set out in 'Social value judgements:
2 principles for the development of NICE guidance'.³

3 When QALYs or life years gained are not used in the analysis, results are difficult to interpret
4 unless one strategy dominates the others with respect to every relevant health outcome and
5 cost.

6 **Additional considerations for this guideline**

7 RRT sustains life when the kidneys can no longer function sufficiently. Based on current NHS
8 reference costs, at a minimum, in-centre dialysis costs around £25,000 per patient per year
9 for adults (higher for children), not including costs such as access creation and management,
10 complications and other health care contacts. Once the kidneys cannot sustain life, no
11 treatment would result in death and therefore zero costs and QALYs. Hence at this point
12 dialysis cannot have a cost effectiveness ratio within the range typically considered cost
13 effective by NICE – the ICER cannot be less than the intervention costs in this circumstance,
14 even if life extension is at full health (which will not be the case). For example, even just
15 taking intervention costs alone of £25,000 (in reality there will be additional costs of care) and
16 assuming life extension with a quality of life weight of 0.7 this would result in an ICER of
17 around £36,000. While in modern practice, the 'no dialysis' option is conservative
18 management and dialysis may be started earlier and so immediate death may not be
19 inevitable, this may mean that the difference in costs during this period are reduced, however
20 the magnitude of health benefit during this period will also be reduced as whilst the patient is
21 alive the QALY difference will only be driven by the difference in quality of life alone and so
22 will be much reduced. It is therefore highly unlikely that dialysis would be considered cost
23 effective by usual NICE criteria. However, dialysis has been the standard of care for people
24 with advanced kidney disease for many years despite the clear high costs for the NHS and
25 so it is considered that this can be interpreted as evidence that society consider dialysis
26 worthwhile despite this high cost. In the guideline we therefore started from the assumption
27 that the current standard of care is considered acceptable in knowledge of this issue.

28 This also however results in an issue where new treatments in a dialysis population extend
29 life. Because dialysis treatment is so costly, treatments that are effective in sustaining life
30 may not be cost effective even if similar or less costly to deliver due to the additional costs of
31 dialysis in the additional years of life. Whilst the opportunity cost to the NHS of these
32 additional costs during the additional years of life are real, whether it is appropriate not to
33 recommend such treatments is less straightforward given that the costs are arising from the
34 continuation of a treatment that is accepted. Where this issue occurred this was highlighted
35 to the committee and was considered when interpreting the evidence.

36 In the new health economic analysis undertaken for the guideline results are presented
37 where costs incurred in additional years of life not specifically due to differences between the
38 cost of HDF and HD are excluded, alongside results using the standard NICE reference case
39 for health care interventions.

2.4.40 In the absence of health economic evidence

41 When no relevant published health economic studies were found, and a new analysis was
42 not prioritised, the committee made a qualitative judgement about cost effectiveness by
43 considering expected differences in resource use between options and relevant UK NHS unit
44 costs, alongside the results of the review of clinical effectiveness evidence.

45 The UK NHS costs reported in the guideline are those that were presented to the committee
46 and were correct at the time recommendations were drafted. They may have changed
47 subsequently before the time of publication. However, we have no reason to believe they
48 have changed substantially.

2.5.1 Developing recommendations

- 2 Over the course of the guideline development process, the committee was presented with:
- 3 • Summaries of clinical and health economic evidence and quality (as presented in
 - 4 evidence reports [A–M]).
 - 5 • Evidence tables of the clinical and health economic evidence reviewed from the literature.
 - 6 All evidence tables can be found in appendices to the relevant evidence reports.
 - 7 • Forest plots (in appendices to the relevant evidence reports).
 - 8 • A description of the methods and results of the cost-effectiveness analysis undertaken for
 - 9 the guideline (in a separate economic analysis report).

10 Recommendations were drafted on the basis of the committee’s interpretation of the
11 available evidence, taking into account the balance of benefits, harms and costs between
12 different courses of action. This was either done formally in an economic model, or
13 informally. Firstly, the net clinical benefit over harm (clinical effectiveness) was considered,
14 focusing on the critical outcomes. When this was done informally, the committee took into
15 account the clinical benefits and harms when one intervention was compared with another.
16 The assessment of net clinical benefit was moderated by the importance placed on the
17 outcomes (the committee’s values and preferences), and the confidence the committee had
18 in the evidence (evidence quality). Secondly, the committee assessed whether the net
19 clinical benefit justified any differences in costs between the alternative interventions.

20 When clinical and health economic evidence was of poor quality, conflicting or absent, the
21 committee drafted recommendations based on its expert opinion. The considerations for
22 making consensus-based recommendations include the balance between potential harms
23 and benefits, the economic costs compared to the economic benefits, current practices,
24 recommendations made in other relevant guidelines, patient preferences and equality issues.
25 The consensus recommendations were agreed through discussions in the committee. The
26 committee also considered whether the uncertainty was sufficient to justify delaying making a
27 recommendation to await further research, taking into account the potential harm of failing to
28 make a clear recommendation (see section 2.5.1 below).

29 The committee considered the appropriate ‘strength’ of each recommendation. This takes
30 into account the quality of the evidence but is conceptually different. Some recommendations
31 are ‘strong’ in that the committee believes that the vast majority of healthcare and other
32 professionals and patients would choose a particular intervention if they considered the
33 evidence in the same way that the committee has. This is generally the case if the benefits
34 clearly outweigh the harms for most people and the intervention is likely to be cost effective.
35 However, there is often a closer balance between benefits and harms, and some patients
36 would not choose an intervention whereas others would. This may happen, for example, if
37 some patients are particularly averse to some side effect and others are not. In these
38 circumstances the recommendation is generally weaker, although it may be possible to make
39 stronger recommendations about specific groups of patients.

40 The committee focused on the following factors in agreeing the wording of the
41 recommendations:

- 42 • The actions health professionals need to take.
- 43 • The information readers need to know.
- 44 • The strength of the recommendation (for example the word ‘offer’ was used for strong
- 45 recommendations and ‘consider’ for weaker recommendations).
- 46 • The involvement of patients (and their carers if needed) in decisions on treatment and
- 47 care.
- 48 • Consistency with NICE’s standard advice on recommendations about drugs, waiting times
- 49 and ineffective interventions (see section 9.2 in the NICE guidelines manual²).

- 1 The main considerations specific to each recommendation are outlined in 'The committee's
2 discussion of the evidence' section within each evidence report.

2.5.13 Research recommendations

- 4 When areas were identified for which good evidence was lacking, the committee considered
5 making recommendations for future research. Decisions about the inclusion of a research
6 recommendation were based on factors such as:
- 7 • the importance to patients or the population
 - 8 • national priorities
 - 9 • potential impact on the NHS and future NICE guidance
 - 10 • ethical and technical feasibility.

2.5.21 Validation process

- 12 This guidance is subject to a 6-week public consultation and feedback as part of the quality
13 assurance and peer review of the document. All comments received from registered
14 stakeholders are responded to in turn and posted on the NICE website.

2.5.35 Updating the guideline

- 16 Following publication, and in accordance with the NICE guidelines manual, NICE will
17 undertake a review of whether the evidence base has progressed significantly to alter the
18 guideline recommendations and warrant an update.

2.5.49 Disclaimer

- 20 Healthcare providers need to use clinical judgement, knowledge and expertise when
21 deciding whether it is appropriate to apply guidelines. The recommendations cited here are a
22 guide and may not be appropriate for use in all situations. The decision to adopt any of the
23 recommendations cited here must be made by practitioners in light of individual patient
24 circumstances, the wishes of the patient, clinical expertise and resources.
- 25 The National Guideline Centre disclaims any responsibility for damages arising out of the use
26 or non-use of this guideline and the literature used in support of this guideline.

2.5.27 Funding

- 28 The National Guideline Centre was commissioned by the National Institute for Health and
29 Care Excellence to undertake the work on this guideline.
- 30

3₁ Additional information

2 This guideline considered non-randomised evidence for a number of reviews where
3 randomised evidence was scarce or non-existent. Before starting any evidence reviews, the
4 committee discussed appropriate key confounders that any non-randomised study must have
5 adjusted for (or considered in propensity score matching or other appropriate methods) in
6 order to reduce selection bias to a degree that the committee would have confidence in the
7 results. The committee chose age, ethnicity, co-morbidities and baseline health as key
8 confounders, as they agreed that each had the potential to affect clinical outcomes. These
9 confounding factors were defined in the review protocols. Whether or not baseline health had
10 been adequately adjusted for was a subjective decision that was confirmed with the senior
11 research fellow on the guideline, examples of baseline health measures that were deemed
12 adequate included baseline quality of life, comprehensive lists of co-existing conditions,
13 frailty scores and combinations of eGFR and other markers such as BMI or albumin.
14 Accurately adjusting for baseline health is challenging and the committee noted that its
15 inclusion as a key confounder reduced the selection bias in the presented evidence but did
16 not eliminate it entirely. For some reviews, the key confounder criteria were modified and this
17 is specified within the reviews themselves. When a review required inclusion of non-
18 randomised studies, the committee prioritised those studies that were non-randomised but
19 still involved assessing outcomes from cohorts experiencing interventions over time (either
20 retrospectively or prospectively).

21

22

4₁ Acronyms and abbreviations

2

Acronym or abbreviation	Description
AKI	Acute kidney injury
AVF	Arteriovenous fistulae
APD	Automated peritoneal dialysis
BAME	Black, Asian and minority ethnic
BMI	Body mass index
BP	Blood pressure
CAPD	Continuous ambulatory peritoneal dialysis
CCPD	Continuous cycling peritoneal dialysis
CEA	Cost-effectiveness analysis
CI	Confidence interval
CKD	Chronic kidney disease
CUA	Cost-utility analysis
eGFR	Estimated glomerular filtration rate
EPS	Encapsulating peritoneal sclerosis
EQ-5D	EuroQol 5-dimension
ESRD	End stage renal disease
FU	Follow-up
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HD	Haemodialysis
HDF	Haemodiafiltration
HR	Hazard ratio
ICER	Incremental cost-effectiveness ratio
KDQ	Kidney Disease Questionnaire
MID	Minimally important difference
NGC	National Guideline Centre
NICE	National Institute for Health and Care Excellence
NRS	Non-randomised study
OECD	Organisation for Economic Co-operation and Development
OR	Odds ratio
PD	Peritoneal dialysis
QALY	Quality-adjusted life year
RCT	Randomised controlled trial
RR	Risk ratio
RRT	Renal replacement therapy
SF-12	12-Item Short Form Health Survey
SF-36	36-Item Short Form Health Survey
TTE	Time to event (data)
UFF	Ultrafiltration failure

5.1 Glossary

2 The NICE Glossary can be found at www.nice.org.uk/glossary.

5.1.3 Guideline-specific terms

4

Term	Definition
Acute kidney injury (AKI)	Previously known as acute renal failure. This is a wide spectrum of injury to the kidneys (not just failure) and is characterised by rapid loss of renal function.
Advance care plan	A formal care plan that includes details about the person's condition, decisions made with them, and where appropriate their parents or carers (for example about managing symptoms), and their wishes and ambitions. This plan is a core element of their palliative care.
Arteriovenous fistula (AVF)	A link created between an artery and vein needed for haemodialysis.
Chronic kidney disease (CKD)	Abnormalities of kidney function and/or structure, present for more than three months, with implications for health.
Conservative management	Full supportive management (including the control of symptoms and complications and advance care planning) for those in the later stages of CKD who, in conjunction with carers and the clinical team, decide against renal replacement therapy.
Dialysis via vascular access	An umbrella term to incorporate both haemodialysis and haemodiafiltration.
Estimated glomerular filtration rate	Assessment of how much blood is filtered by the kidneys, estimated using a mathematical formula that compares a person's size, age, sex, and race to serum creatinine levels.
Encapsulating peritoneal sclerosis	A rare complication of long-term peritoneal dialysis associated with extensive thickening and fibrosis of the peritoneum that can severely affect the bowel such that it becomes partially or even fully obstructed.
End of life care	End of life care includes the care and support given in the final days, weeks and months of life, and the planning and preparation for this.
Fluid allowance	Daily allowable fluid intake. This is necessary because the kidneys are unable to regulate the amount of fluid in the body.
Haemodialysis (HD)	A form of dialysis in which the blood is cleaned outside the body in a dialysis machine.
Home haemodialysis	Haemodialysis available for suitable patients with support at home.
Haemodiafiltration (HDF)	A form of dialysis which removes uraemic solutes beyond the usual range of small molecules removed in conventional haemodialysis.
Hyperkalaemia	Abnormally high potassium concentration in the blood, most often due to defective renal excretion, as in kidney disease.
Hyperphosphataemia	An abnormally elevated level of phosphate in the blood.
Later stages of chronic kidney disease (CKD)	Stage 4 or 5 CKD (and stage 3 in the context of initiating planning to the later stages).
Peritoneal dialysis (PD)	A form of dialysis that takes place inside the patient's peritoneal cavity.
Pre-emptive transplant	A kidney transplant before dialysis begins.
Renal replacement therapy (RRT)	A term used to encompass life-supporting treatments for severe AKI or stage 5 chronic kidney disease. It includes: haemodialysis, haemofiltration, haemodiafiltration, peritoneal dialysis and renal transplantation. These are collectively referred to in the guideline as modalities of RRT.

Term	Definition
Shared decision making	Shared decision making is an approach where clinicians and patients communicate together using the best available evidence when faced with the task of making decisions, where patients are supported to deliberate about the possible attributes and consequences of options, to arrive at informed preferences in making a determination about the best action and which respects patient autonomy, where this is desired, ethical and legal.
Ultrafiltration	The removal of water in haemodialysis.
Unplanned start	RRT initiated without prior planning or preparation, often as a result of AKI.
Uraemia	An excess of urea and nitrogen based wastes in the blood.
Vascular access	Access using a vein for haemodialysis.

5.2.1 General terms

Term	Definition
Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Algorithm (in guidelines)	A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.
Arm (of a clinical study)	Subsection of individuals within a study who receive one particular intervention, for example placebo arm.
Association	Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal.
Base-case analysis	In an economic evaluation, this is the main analysis based on the most plausible estimate of each input. In contrast, see Sensitivity analysis.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bayesian analysis	A method of statistics, where a statistic is estimated by combining established information or belief (the 'prior') with new evidence (the 'likelihood') to give a revised estimate (the 'posterior').
Before-and-after study	A study that investigates the effects of an intervention by measuring particular characteristics of a population both before and after taking the intervention, and assessing any change that occurs.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.

Term	Definition
Blinding	<p>A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias.</p> <p>A single-blinded study is one in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is one in which neither patients nor the researchers and doctors know which study group the patients are in. A triple blind study is one in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.</p>
Carer (caregiver)	<p>Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.</p>
Case–control study	<p>A study to find out the cause(s) of a disease or condition. This is done by comparing a group of patients who have the disease or condition (cases) with a group of people who do not have it (controls) but who are otherwise as similar as possible (in characteristics thought to be unrelated to the causes of the disease or condition). This means the researcher can look for aspects of their lives that differ to see if they may cause the condition.</p> <p>For example, a group of people with lung cancer might be compared with a group of people the same age that do not have lung cancer. The researcher could compare how long both groups had been exposed to tobacco smoke. Such studies are retrospective because they look back in time from the outcome to the possible causes of a disease or condition.</p>
Case series	<p>Report of a number of cases of a given disease, usually covering the course of the disease and the response to treatment. There is no comparison (control) group of patients.</p>
Clinical efficacy	<p>The extent to which an intervention is active when studied under controlled research conditions.</p>
Clinical effectiveness	<p>How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials.</p> <p>Clinical effectiveness is not the same as efficacy.</p>
Clinician	<p>A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.</p>
Cochrane Review	<p>The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration).</p>
Cohort study	<p>A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study.</p>
Comorbidity	<p>A disease or condition that someone has in addition to the health problem being studied or treated.</p>
Comparability	<p>Similarity of the groups in characteristics likely to affect the study results (such as health status or age).</p>
Concordance	<p>This is a recent term whose meaning has changed. It was initially applied to the consultation process in which doctor and patient agree therapeutic decisions that incorporate their respective views, but now includes patient support in medicine taking as well as prescribing</p>

Term	Definition
	communication. Concordance reflects social values but does not address medicine-taking and may not lead to improved adherence.
Confidence interval (CI)	<p>There is always some uncertainty in research. This is because a small group of patients is studied to predict the effects of a treatment on the wider population. The confidence interval is a way of expressing how certain we are about the findings from a study, using statistics. It gives a range of results that is likely to include the 'true' value for the population.</p> <p>The CI is usually stated as '95% CI', which means that the range of values has a 95 in a 100 chance of including the 'true' value. For example, a study may state that "based on our sample findings, we are 95% certain that the 'true' population blood pressure is not higher than 150 and not lower than 110". In such a case the 95% CI would be 110 to 150.</p> <p>A wide confidence interval indicates a lack of certainty about the true effect of the test or treatment – often because a small group of patients has been studied. A narrow confidence interval indicates a more precise estimate (for example, if a large number of patients have been studied).</p>
Confounding factor	<p>Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.</p> <p>For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor.</p>
Consensus methods	<p>Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.</p>
Control group	<p>A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences.</p> <p>Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.</p>
Cost–benefit analysis (CBA)	<p>Cost–benefit analysis is one of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs.</p>
Cost–consequences analysis (CCA)	<p>Cost–consequences analysis is one of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost–benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.</p>
Cost-effectiveness analysis (CEA)	<p>Cost-effectiveness analysis is one of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks</p>

Term	Definition
	avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).
Cost-effectiveness model	An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.
Cost–utility analysis (CUA)	Cost–utility analysis is one of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.
Credible interval (CrI)	The Bayesian equivalent of a confidence interval.
Decision analysis	An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the clinician through a succession of possible scenarios, actions and outcomes.
Deterministic analysis	In economic evaluation, this is an analysis that uses a point estimate for each input. In contrast, see Probabilistic analysis
Diagnostic odds ratio	The diagnostic odds ratio is a measure of the effectiveness of a diagnostic test. It is defined as the ratio of the odds of the test being positive if the subject has a disease relative to the odds of the test being positive if the subject does not have the disease.
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Disutility	The loss of quality of life associated with having a disease or condition. See Utility
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals. There are several types of economic evaluation: cost–benefit analysis, cost–consequences analysis, cost–effectiveness analysis, cost–minimisation analysis and cost–utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention.
Effect (as in effect measure, treatment effect, estimate of effect, effect size)	A measure that shows the magnitude of the outcome in one group compared with that in a control group. For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%. The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.

Term	Definition
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
Epidemiological study	The study of a disease within a population, defining its incidence and prevalence and examining the roles of external influences (for example, infection, diet) and interventions.
EQ-5D (EuroQoL 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients).
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore cost effective and should be preferred, other things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
Gold standard	A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease.
GRADE, GRADE profile	A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile.
Harms	Adverse effects of an intervention.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life (HRQoL)	A measure of the effects of an illness to see how it affects someone's day-to-day life.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.

Term	Definition
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using one test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for one treatment compared with another.
Incremental net benefit (INB)	The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: (£20,000 × QALYs gained) – Incremental cost.
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).
Intention-to-treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.
Intervention	In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Kappa statistic	A statistical measure of inter-rater agreement that takes into account the agreement occurring by chance.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Likelihood ratio	The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity).
Long-term care	Residential care in a home that may include skilled nursing care and help with everyday activities. This includes nursing homes and residential homes.
Logistic regression or Logit model	In statistics, logistic regression is a type of analysis used for predicting the outcome of a binary dependent variable based on one or more predictor variables. It can be used to estimate the log of the odds (known as the 'logit').
Loss to follow-up	A patient, or the proportion of patients, actively participating in a clinical trial at the beginning, but whom the researchers were unable to trace or contact by the point of follow-up in the trial
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).

Term	Definition
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Multivariate model	A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. It is calculated as follows: $TN/(TN+FN)$
Net monetary benefit (NMB)	The value in monetary terms of an intervention net of its cost. The NMB can be calculated for a given cost-effectiveness threshold. If the threshold is £20,000 per QALY gained then the NMB for an intervention is calculated as: $(£20,000 \times \text{mean QALYs}) - \text{mean cost}$. The most preferable option (that is, the most clinically effective option to have an ICER below the threshold selected) will be the treatment with the highest NMB.
Non-randomised intervention study	A quantitative study investigating the effectiveness of an intervention that does not use randomisation to allocate patients (or units) to treatment groups. Non-randomised studies include observational studies, where allocation to groups occurs through usual treatment decisions or people's preferences. Non-randomised studies can also be experimental, where the investigator has some degree of control over the allocation of treatments. Non-randomised intervention studies can use a number of different study designs, and include cohort studies, case-control studies, controlled before-and-after studies, interrupted-time-series studies and quasi-randomised controlled trials.
Number needed to treat (NNT)	The average number of patients who need to be treated to get a positive outcome. For example, if the NNT is 4, then 4 patients would have to be treated to ensure 1 of them gets better. The closer the NNT is to 1, the better the treatment. For example, if you give a stroke prevention drug to 20 people before 1 stroke is prevented, the number needed to treat is 20. See also number needed to harm, absolute risk reduction.
Observational study	Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in one characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening. There is a greater risk of selection bias than in experimental studies.
Odds ratio	Odds are a way to represent how likely it is that something will happen (the probability). An odds ratio compares the probability of something in one group with the probability of the same thing in another. An odds ratio of 1 between 2 groups would show that the probability of the event (for example a person developing a disease, or a treatment working) is the same for both. An odds ratio greater than 1 means the event is more likely in the first group. An odds ratio less than 1 means that the event is less likely in the first group. Sometimes probability can be compared across more than 2 groups – in this case, one of the groups is chosen as the 'reference category', and the odds ratio is calculated for each group compared with the reference category. For example, to compare the risk of dying from lung cancer for non-smokers, occasional smokers and

Term	Definition
	regular smokers, non-smokers could be used as the reference category. Odds ratios would be worked out for occasional smokers compared with non-smokers and for regular smokers compared with non-smokers. See also confidence interval, risk ratio.
Opportunity cost	The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.
Outcome	The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone's health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins.
P value	<p>The p value is a statistical measure that indicates whether or not an effect is statistically significant.</p> <p>For example, if a study comparing 2 treatments found that one seems more effective than the other, the p value is the probability of obtaining these results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.</p> <p>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.</p>
Perioperative	The period from admission through surgery until discharge, encompassing the preoperative and postoperative periods.
Placebo	A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.
Polypharmacy	The use or prescription of multiple medications.
Posterior distribution	In Bayesian statistics this is the probability distribution for a statistic based after combining established information or belief (the prior) with new evidence (the likelihood).
Positive predictive value (PPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. It is calculated as follows: $TP/(TP+FP)$
Postoperative	Pertaining to the period after patients leave the operating theatre, following surgery.
Post-test probability	In diagnostic tests: The proportion of patients with that particular test result who have the target disorder (post-test odds/[1 plus post-test odds]).
Power (statistical)	The ability to demonstrate an association when one exists. Power is related to sample size; the larger the sample size, the greater the

Term	Definition
	power and the lower the risk that a possible association could be missed.
Preoperative	The period before surgery commences.
Pre-test probability	In diagnostic tests: The proportion of people with the target disorder in the population at risk at a specific time point or time interval. Prevalence may depend on how a disorder is diagnosed.
Prevalence	See Pre-test probability.
Prior distribution	In Bayesian statistics this is the probability distribution for a statistic based on previous evidence or belief.
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the one in a study that the power calculation is based on.
Probabilistic analysis	In economic evaluation, this is an analysis that uses a probability distribution for each input. In contrast, see Deterministic analysis.
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group (the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.

Term	Definition
RCT	See 'Randomised controlled trial'.
Receiver operated characteristic (ROC) curve	A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.
Reference standard	The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the one that is routinely used in practice.
Reporting bias	See 'Publication bias'.
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.
Review question	In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.
Risk ratio (RR)	<p>The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke).</p> <p>If both groups face the same level of risk, the risk ratio is 1. If the first group had a risk ratio of 2, subjects in that group would be twice as likely to have the event happen. A risk ratio of less than 1 means the outcome is less likely in the first group. The risk ratio is sometimes referred to as relative risk.</p>
Secondary outcome	An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes.
Selection bias	<p>Selection bias occurs if:</p> <ul style="list-style-type: none"> a) The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or b) There are differences between groups of participants in a study in terms of how likely they are to get better.
Sensitivity	<p>How well a test detects the thing it is testing for.</p> <p>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who don't have the disease (that is, give a 'false positive').</p> <p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p> <p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a 'true negative'). But it would probably also miss some people who were 6 months pregnant (that is, give a 'false negative').</p> <p>Breast screening is a 'real-life' example. The number of women who are recalled for a second breast screening test is relatively high because the test is very sensitive. If it were made more specific, people who don't have the disease would be less likely to be called</p>

Term	Definition
	back for a second test but more women who have the disease would be missed.
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p> <p>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).</p>
Significance (statistical)	A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 ($p < 0.05$).
Specificity	<p>The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.</p> <p>See related term 'Sensitivity'.</p> <p>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.</p>
Stakeholder	<p>An organisation with an interest in a topic that NICE is developing a guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:</p> <ul style="list-style-type: none"> • manufacturers of drugs or equipment • national patient and carer organisations • NHS organisations • organisations representing healthcare professionals.
State transition model	See Markov model
Systematic review	A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.
Time horizon	The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.
Transition probability	In a state transition model (Markov model), this is the probability of moving from one health state to another over a specific period of time.
Treatment allocation	Assigning a participant to a particular arm of a trial.
Univariate	Analysis which separately explores each variable in a data set.
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost-utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs).

1
2

1 References

2

3 1. GRADE Working Group. The Grading of Recommendations Assessment,
4 Development and Evaluation (GRADE) Working Group website. 2011. Available from:
5 <http://www.gradeworkinggroup.org/> Last accessed:

6 2. National Institute for Health and Care Excellence. Developing NICE guidelines: the
7 manual. London. National Institute for Health and Care Excellence, 2014. Available
8 from: [https://www.nice.org.uk/media/default/about/what-we-do/our-](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf)
9 [programmes/developing-nice-guidelines-the-manual.pdf](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf)

10 3. National Institute for Health and Clinical Excellence. Social value judgements:
11 principles for the development of NICE guidance. London. National Institute for
12 Health and Clinical Excellence, 2008. Available from:
13 [https://www.nice.org.uk/media/default/about/what-we-do/research-and-](https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf)
14 [development/social-value-judgements-principles-for-the-development-of-nice-](https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf)
15 [guidance.pdf](https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf)

16 4. National Institute for Health and Clinical Excellence. Guide to the methods of
17 technology appraisal 2013. London. National Institute for Health and Clinical
18 Excellence, 2013. Available from: <http://publications.nice.org.uk/pmg9>

19 5. Organisation for Economic Co-operation and Development (OECD). Purchasing
20 power parities (PPP). Available from: <http://www.oecd.org/std/prices-ppp/> Last
21 accessed: 13/12/2017.

22 6. Review Manager (RevMan) [Computer program]. Version 5. Copenhagen. The Nordic
23 Cochrane Centre, The Cochrane Collaboration, 2015. Available from:
24 <http://tech.cochrane.org/Revman>

25